The influence over a period of 8 years of patterns of prescribing palizivumab for patients with and without congenitally malformed hearts, and in admissions to paediatric intensive care

Cardiology in the Young

Volumn 19, Issue 4, 2009, Pages 346-351

  Turner, Alastair ^a   Begg, Colin ^a   Smith, Benjamin ^a   Coutts, Jonathan ^b  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b QUEEN MOTHER S HOSPITAL   (United Kingdom)

Author keywords

Bronchiolitis; Congenital heart disease; Immunisation; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

AORTA COARCTATION; ARTICLE; CHILD; CLINICAL TRIAL; CONGENITAL HEART DISEASE; FALLOT TETRALOGY; GREAT VESSELS TRANSPOSITION; HEART LEFT RIGHT SHUNT; HEART RIGHT VENTRICLE DOUBLE OUTLET; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; PRESCRIPTION; PROSPECTIVE STUDY; PULMONARY VALVE ATRESIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TRICUSPID VALVE ATRESIA; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DRUG PRESCRIPTIONS; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, PEDIATRIC; PATIENT ADMISSION; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SCOTLAND; TIME FACTORS;

EID: 70349208951     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951109003771     Document Type: Article

References (11)

1. Simoes E. Respiratory syncytial virus infection. Lancet 1999; 354: 847-852.
2. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397-400.
3. IMpact-RSV study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-537.
4. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. A West Midlands Health Technology assessment Group. University of Birmingham 2001.
5. Reeve CA, Whitehall JS, Buettner PG, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006; 42: 253-258.
6. Joint Committee on Vaccination and Immunisation. Minutes of the meeting held on Friday 1st November 2002. www.advisory bodies.doh.gov.uk/jcvi/ mins01nov02.htm
7. Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital heart disease. Cardiol Young 2003; 13: 420-423.
8. Joint Committee on Vaccination and Immunisation. Minutes from the meeting held on 22nd June 2005. www.advisorybodies.doh.gov.uk/jcvi/ mins220605.htm
9. Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch Dis Child 2006; 91: 717.
10. ISD Scotland Scottish Health Statistics, (www.isdscotland.org).
11. Scottish Perinatal and Infant Mortality and Morbidity report 2006, ISD Publications. NHS Scotland. Edinburgh 2007. www.isdscotland.org